Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection - Case Series Report.

Fu, Chunlan; Zhu, Yuanyuan; Huang, Weijia; Luo, Yi; Hu, Yongxian; Huang, He; Sun, Jie

Fu, Chunlan; Zhu, Yuanyuan; Huang, Weijia; Luo, Yi; Hu, Yongxian; Huang, He; Sun, Jie.

Afiliación

Fu C; Department of Hematology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, Zhejiang, 311800, People's Republic of China.
Zhu Y; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.
Huang W; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.
Luo Y; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.
Hu Y; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.
Huang H; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.
Sun J; Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, People's Republic of China.

Infect Drug Resist ; 17: 31-39, 2024.

Article en En | MEDLINE | ID: mdl-38197068

Palabras clave

COVID-19; hematologic malignancy; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Infect Drug Resist Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google